Two Studies Support Short Dual Antiplatelet Therapy With Abbott’s Xience DES
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
You may also be interested in...
The agency approved the Xience stents as suitable for patients at high bleeding-risk who can only stay on antiplatelet therapy for four weeks. Abbott also announced that it has received FDA approval and European CE mark approval for its Xience Skypoint stent.
The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.
The agency approved Medtronic's zotarolimus-eluting coronary stent for patients with a high bleeding risk who are treated with one month of dual-antiplatelet therapy.